Biohaven Ltd. (NYSE:BHVN – Get Free Report) traded up 9.6% on Thursday. The stock traded as high as $13.94 and last traded at $14.1350. Approximately 295,513 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 2,742,931 shares. The stock had previously closed at $12.90.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on BHVN shares. HC Wainwright reissued a “neutral” rating and set a $10.00 price target on shares of Biohaven in a research report on Thursday, September 10th. Weiss Ratings upgraded Biohaven from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a report on Thursday, October 8th. TD Cowen restated a “buy” rating on shares of Biohaven in a research report on Wednesday, August 26th. Finally, Wall Street Zen cut shares of Biohaven from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Biohaven has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.
Check Out Our Latest Analysis on Biohaven
Biohaven Price Performance
The stock has a market capitalization of $2.12 billion, a P/E ratio of -3.64 and a beta of 1.36. The company has a 50 day moving average of $13.41 and a 200-day moving average of $12.37. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 21.23.
Institutional Trading of Biohaven
Hedge funds have recently bought and sold shares of the company. Sterling Capital Management LLC grew its holdings in Biohaven by 847.5% in the 3rd quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock worth $59,000 after buying an additional 3,975 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in Biohaven during the 2nd quarter valued at $60,000. Essential Partners LLC raised its stake in Biohaven by 31.7% during the 1st quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock valued at $76,000 after acquiring an additional 2,169 shares in the last quarter. IFP Advisors Inc boosted its position in Biohaven by 43.3% during the 2nd quarter. IFP Advisors Inc now owns 6,011 shares of the company’s stock worth $89,000 after acquiring an additional 1,816 shares during the period. Finally, Allworth Financial LP lifted its holdings in Biohaven by 10.4% in the third quarter. Allworth Financial LP now owns 8,672 shares of the company’s stock worth $116,000 after purchasing an additional 814 shares during the period. 88.78% of the stock is currently owned by institutional investors.
About Biohaven
Biohaven Ltd. is a clinical-stage biopharmaceutical company developing treatments for neurological, immunological and other serious diseases. Its research programs include potential therapies for epilepsy and autoimmune conditions, as well as medicines designed to target disease-related proteins and antibodies. The company’s pipeline includes investigational candidates that act on ion channels and immune pathways. These programs are in development and are not approved medicines; Biohaven does not have a marketed product portfolio.
Featured Articles
- Five stocks we like better than Biohaven
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.
